Corporate Policies & Patents

This policy establishes an effective, accountable, and transparent framework for ensuring compliance with the requirements of the relevant obligations defined under security laws including but not limited to, the European Regulation of 16 April 2014 on Market Abuse effective on 3 July 2016, its implementing legislation, as well as the positions and recommendations of the European Securities and Markets Authority and the French financial markets regulator named Autorité des Marchés Financiers), as defined below.

Median Technologies AI/ML tech-based Software as a Medical Device (SaMD) suite performing medical image analysis to support cancer diagnosis contains methods protected by patents granted in the U.S and pending in other countries. This webpage is provided to satisfy the virtual patent marking provisions of the America Invents Act and other jurisdictions.

• US 11, 810, 299
• US 12, 272, 063

The rise of Artificial Intelligence presents significant opportunities and cost-saving potential for organizations, driving its adoption across a multitude of sectors. However, integrating AI into products, especially medical devices, and internal processes without a robust governance framework exposes companies to considerable legal, financial, and reputational risks. Effective AI governance strikes a balance between fostering innovation and ensuring compliance with existing regulations, ethical standards, and commercial imperatives.